TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment
- 1Clinical Safety & Pharmacovigilance, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
- 2Epidemiology, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
- 3Global Oncology Medical Affairs, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
Abstract
Aims: To assess hepatic safety for adults with pexidartinib-treated tenosynovial giant cell tumor (TGCT) from the 6-year retrospective evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program.
Methods: Retrospective hepatic safety data (08/2019–08/2025) were collected from healthcare professionals and patients in the tREMS Program.
Results: During the current reporting period (06/2024–08/2025), 133/145 (91.7%) new patients received ≥1 pexidartinib dispense. For the cumulative 6-year reporting period, 878/929 (94.5%) patients received ≥1 pexidartinib dispense. Overall, 51/878 (5.8%) patients had adverse events or laboratory abnormalities suggesting serious and potentially fatal liver injury; of these, 47 (92.2%) discontinued pexidartinib, 3 (5.9%) interrupted doses, and 1 (2.0%) continued at the same dose. By August 2025, 34 (66.7%) events were fully resolved, 6 (11.8%) were resolving, 9 (17.6%) were unresolved, and 2 (3.9%) had unknown outcomes. There were no cases of irreversible liver injury, additional cases of vanishing bile duct syndrome, or new safety signals during the current reporting period.
Conclusions: The tREMS Program effectively mitigates hepatotoxicity risk through prompt intervention/reporting and timely dose modifications for adverse event management. When used according to guidelines, pexidartinib is a therapeutic option for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Related
- Diagnostic performance, implementation fidelity, and costs of the World Health Organization three-test HIV testing strategy in Malawi: a national retrospective evaluation
- Improving the detection, assessment, management and prevention of delirium in palliative care units (the DAMPen-Delirium II study): protocol for an implementation-to-target Type III hybrid effectiveness-implementation cluster randomised-controlled trial, economic evaluation and process evaluation of the Creating Learning Environments for Compassionate Care-Palliative (CLECC-Pal) implementation strategy.
- Evaluation of a severity-based surgical strategy for refractory Mooren’s ulcer: A retrospective series with long-term follow-up
- Ocular tissue distribution of Ocular Surface Immune Globulins Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of ADC-Associated Ocular Toxicity
- Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
BibTeX
@article{rajper2026turalio,
title = {{TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment}},
author = {Abdul Waheed Rajper and Charles Dharmani and Lalitha Chilakapati and Oluwatosin Fofah and Margaret J. Wooddell},
journal = {Patient Related Outcome Measures},
year = {2026},
month = nov,
doi = {10.1080/1179271x.2026.2757394},
url = {https://doi.org/10.1080/1179271x.2026.2757394},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment
AU - Abdul Waheed Rajper
AU - Charles Dharmani
AU - Lalitha Chilakapati
AU - Oluwatosin Fofah
AU - Margaret J. Wooddell
PY - 2026
DA - 2026/11/05
JO - Patient Related Outcome Measures
DO - 10.1080/1179271x.2026.2757394
UR - https://doi.org/10.1080/1179271x.2026.2757394
AB - Aims: To assess hepatic safety for adults with pexidartinib-treated tenosynovial giant cell tumor (TGCT) from the 6-year retrospective evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program. Methods: Retrospective hepatic safety data (08/2019–08/2025) were collected from healthcare professionals and patients in the tREMS Program. Results: During the current reporting period (06/2024–08/2025), 133/145 (91.7%) new patients received ≥1 pexidartinib dispense. For the cumulative 6-year reporting period, 878/929 (94.5%) patients received ≥1 pexidartinib dispense. Overall, 51/878 (5.8%) patients had adverse events or laboratory abnormalities suggesting serious and potentially fatal liver injury; of these, 47 (92.2%) discontinued pexidartinib, 3 (5.9%) interrupted doses, and 1 (2.0%) continued at the same dose. By August 2025, 34 (66.7%) events were fully resolved, 6 (11.8%) were resolving, 9 (17.6%) were unresolved, and 2 (3.9%) had unknown outcomes. There were no cases of irreversible liver injury, additional cases of vanishing bile duct syndrome, or new safety signals during the current reporting period. Conclusions: The tREMS Program effectively mitigates hepatotoxicity risk through prompt intervention/reporting and timely dose modifications for adverse event management. When used according to guidelines, pexidartinib is a therapeutic option for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
SN - 1179-271X
ER -